CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases

• Main Authors: Olusiji A. Akinrinmade, Shivan Chetty, Adebukola K. Daramola, Mukit-ul Islam, Theo Thepen, Stefan Barth
• Format: Article
• Language: English
• Published: MDPI AG 2017-09-01
• Series: Biomedicines
• Subjects: CD64; immunotherapy; immunotoxins; human cytolytic fusion protein; dysregulated macrophage; chronic inflammatory disease
• Online Access: https://www.mdpi.com/2227-9059/5/3/56

To date, no curative therapy is available for the treatment of most chronic inflammatory diseases such as atopic dermatitis, rheumatoid arthritis, or autoimmune disorders. Current treatments require a lifetime supply for patients to alleviate clinical symptoms and are unable to stop the course of disease. In contrast, a new series of immunotherapeutic agents targeting the Fc γ receptor I (CD64) have emerged and demonstrated significant clinical potential to actually resolving chronic inflammation driven by M1-type dysregulated macrophages. This subpopulation plays a key role in the initiation and maintenance of a series of chronic diseases. The novel recombinant M1-specific immunotherapeutics offer the prospect of highly effective treatment strategies as they have been shown to selectively eliminate the disease-causing macrophage subpopulations. In this review, we provide a detailed summary of the data generated, together with the advantages and the clinical potential of CD64-based targeted therapies for the treatment of chronic inflammatory diseases.